Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical errors hearing

Executive Summary

Senate Appropriations/Labor & Health Subcommittee will hold a hearing on medical errors Jan. 25. The witness list includes Joint Commission on Accreditation of Health Organizations President Dennis O'Leary, MD; Veterans Health Administration National Center for Patient Safety Director James Bagian, MD; Veterans Affairs Acting Undersecretary for Health Thomas Garthwaite, MD; Institute of Medicine Quality of Health Care in America Committee President Molly Coye, MD; and Florida Circuit Court Judge Joe Donahey. The Senate Health Committee also has a medical errors hearing scheduled for Jan. 25 (1"The Pink Sheet" Jan. 17, In Brief)

You may also be interested in...



Medical errors hearing

Senate Health Committee Jan. 25 hearing on the Institute of Medicine report on medical errors will include testimony from Harvard's Lucian Leape, MD, one of the IoM study authors, as well as former Surgeon General C. Everett Koop and Olympic gold medallist Gail Deavers, a medical error victim. A second panel will include American Nurses Association President Mary Foley, Pacific Business Group on Health Medical Director Arnold Milstein, MD, and representatives from the American Medical Association and American Hospital Association. Committee Chairman Jeffords (R-Vt.) is expected to hold at least two more hearings on the topic of patient safety (1"The Pink Sheet" Jan. 10, p. 15)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel